1
Country: USA | Funding: $652M
Apogee Therapeutics operates pipeline candidates designed to treat inflammatory and immunological disorders.
Apogee Therapeutics operates pipeline candidates designed to treat inflammatory and immunological disorders.
2
Country: USA | Funding: $637M
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
3
Country: USA | Funding: $558M
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
4
Country: USA | Funding: $441.6M
Ventyx Biosciences develops a drug for inflammatory bowel disease
Ventyx Biosciences develops a drug for inflammatory bowel disease
5
Country: USA | Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
6
Country: USA | Funding: $356.4M
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
7
Country: China | Funding: $312.8M
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
8
Country: USA | Funding: $276.8M
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
9
Country: USA | Funding: $259.9M
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments.
10
Country: USA | Funding: $237.5M
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
11
Country: USA | Funding: $207M
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
12
Country: China | Funding: $195M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
13
Country: USA | Funding: $176M
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
14
Country: Netherlands | Funding: $149.4M
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
15
Country: USA | Funding: $148M
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
16
Country: USA | Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
17
Country: USA | Funding: $95M
Osiris Therapeutics is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. One of its products, Stromagen was used to treat breast cancer in clinical trials.
Osiris Therapeutics is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. One of its products, Stromagen was used to treat breast cancer in clinical trials.
18
Country: Switzerland | Funding: $87.1M
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
19
Country: Switzerland | Funding: $54.6M
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
20
Country: USA | Funding: $11.4M
PureTech Health is developing differentiated medicines for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases
PureTech Health is developing differentiated medicines for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases
